Page last updated: 2024-11-05

methallenestril

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Methallenestril is a synthetic nonsteroidal estrogen that was developed in the 1950s. It was initially marketed as a treatment for menopausal symptoms and breast cancer. However, its use has been largely discontinued due to concerns about its potential side effects. It is a potent estrogen that acts by binding to estrogen receptors in the body. Its synthesis involves a multi-step process starting from a substituted naphthalene derivative. Research on methallenestril has focused on its effects on the endocrine system, reproductive system, and breast cancer cells. Studies have shown that it can induce cell proliferation and tumor growth in certain tissues. Methallenestril is no longer widely used due to its adverse effects, but it remains an important compound for understanding the mechanisms of estrogen action and the development of new drugs. '

methallenestril: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10599
CHEMBL ID1697842
CHEBI ID6808
SCHEMBL ID517936
MeSH IDM0046561

Synonyms (54)

Synonym
2,2-dimethyl-3-[6-(methyloxy)naphthalen-2-yl]pentanoic acid
methallenoestril
2-naphthalenepropionic acid, beta-ethyl-6-methoxy-alpha,alpha-dimethyl-
methallenestril [inn]
vallestril
methallenestrilum [inn-latin]
methallenestrol
3-(6-methoxy-2-naphthyl)-3-ethyl-2,2-dimethylpropionsaeure
hsdb 3358
novestrine
ercostrol
methallenoestrolum
einecs 208-232-6
metalenestrilo [spanish]
3-(6-methoxy-2-naphthyl)-2,2-dimethylvaleriansaeure
methallenestrilum [latin]
metalenestrilo [inn-spanish]
2-naphthalenepropanoic acid, beta-ethyl-6-methoxy-alpha,alpha-dimethyl-
3-(6-methoxy-2-naphthyl)-2,2-dimethylpentanoic acid
beta-(6-methoxy-2-naphthyl)-alpha,alpha-dimethylvaleric acid
beta-ethyl-6-methoxy-alpha,alpha-dimethyl-2-naphthalenepropionic acid
nsc-81399
nsc81399
nsc81398
nsc-81398
15372-35-7
nsc74235
nsc-74235
methallenestril
C07621
517-18-0
NCIOPEN2_003939
3-(6-methoxynaphthalen-2-yl)-2,2-dimethylpentanoic acid
chebi:6808 ,
CHEMBL1697842
metalenestrilo
methallenestril [inn:ban]
xl025389js ,
unii-xl025389js
methallenestrilum
methallenestril [mart.]
methallenestril [who-dd]
methallenestril [hsdb]
b-ethyl-6-methoxy-a,a-dimethyl-2-naphthalenepropionic acid
methallenestril [mi]
SCHEMBL517936
3-(6-methoxy-2-naphthyl)-2,2-dimethyl-pentanoic acid
.beta.-ethyl-6-methoxy-.alpha.,.alpha.-dimethyl-2-naphthalenepropionic acid
2-naphthalenepropionic acid, .beta.-ethyl-6-methoxy-.alpha.,.alpha.-dimethyl-
2-naphthalenepropanoic acid, .beta.-ethyl-6-methoxy-.alpha.,.alpha.-dimethyl-
DTXSID7023275
Q10843651
2-naphthalenepropanoic acid, beta-ethyl-6-methoxy-alpha,alpha-dimethyl- (9ci)
AKOS040753012

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
naphthalenesAny benzenoid aromatic compound having a skeleton composed of two ortho-fused benzene rings.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (90.91)18.7374
1990's0 (0.00)18.2507
2000's1 (9.09)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.28

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.28 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.14 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.28)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]